42nd week of 2008 patent applcation highlights part 36 |
Patent application number | Title | Published |
20080254043 | Drug For Treating Ischemic Disease - The present invention relates to a pharmaceutical composition which includes a tissue factor inhibitor, which is administered after the onset of a thromboembolic ischemic disease, particularly after thrombus or embolus formation; a secondary thrombus formation inhibitor which includes a tissue factor inhibitor, which is administered after primary thrombus formation; a blood flow reduction inhibitor which includes a tissue factor inhibitor to be administered after thrombus formation or embolism formation; and a method of suppressing secondary thrombus formation by inhibiting tissue factor function following formation of a primary thrombus. | 2008-10-16 |
20080254044 | Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 2008-10-16 |
20080254045 | Modulation of NKT Cell Activity with Antigen-Loaded CD1d Molecules - The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy. | 2008-10-16 |
20080254046 | Method for the Delivery of Exogenous Antigens into the Mhc Class I Presentation Pathway of Cells - The present invention relates to an in vitro method that allows for delivery of exogenous antigens into the MHC class I presentation pathway of antigen-presenting cells (APCs), comprising the following steps: (a) preparation of suitable APCs; (b) determination of suitable specific method parameters for APCs, comprising (1) bringing the cells in contact with a haemolysin such as listeriolysin (LLO) and a marker substance; (2) measuring of marker substance inflow into the cells; and (3) optionally, modifying said specific parameters; and (c) delivery of exogenous antigens into the APCs, by applying the specific parameters calculated in step (b) and bringing the cells in contact with a haemolysin and the antigen of interest. | 2008-10-16 |
20080254047 | Activation of Human Antigen-Presenting Cells Through CLEC-6 - The present invention includes compositions and methods for using novel anti-CLEC-6 antibodies and fragments thereof for modulating the activity of immune cells. | 2008-10-16 |
20080254048 | HE4 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to HE4. Monoclonal antibodies having the binding characteristics of an HE4 antibody of the invention are further provided. Hybridoma cell lines that produce an HE4 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed HE4 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an HE4 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 2008-10-16 |
20080254049 | Composition for Treatment of Colds and Associated Symptoms - A homeopathically designed composition comprising zinc and dilute amounts of | 2008-10-16 |
20080254050 | Antiangiogenic active immunotherapy - Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. | 2008-10-16 |
20080254051 | Use of Native Peptides and Their Optimized Derivatives For Vaccination - The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an optimized immunogenic peptide derived from said native peptide. The invention also concerns vaccination kits which comprise several doses of optimized peptides and of their cognate native peptides. | 2008-10-16 |
20080254052 | MOLECULAR DIFFERENCES BETWEEN SPECIES OF THE M. TUBERCULOSIS COMPLEX - Specific genetic deletion are identified in mycobacteria isolates, including variations in the | 2008-10-16 |
20080254053 | Protocol for treatment of diabetes - A method and composition for reducing highly sensitive C-reactive protein is provided for the treatment of Type I and Type II diabetes which is achieved through the daily administration of a leukotriene inhibitor, an antihistamine and a corticosteroid. The composition may be administered singly or as a single medicament. Typically, the leukotriene inhibitor and antihistamine are administered orally and the steroid nasally infused. | 2008-10-16 |
20080254054 | Fungal Material Stabilisation - A composition and methods of production are described including fungal material, a solid substrate and a biopolymer composition. The composition is described as being stable when stored for at least 7 months and also reduces dust losses normally attributed to fungal compositions. Uses are described for the composition including pest and weed treatments. | 2008-10-16 |
20080254055 | Compositions for Regulation of Hair Growth - Personal care composition comprising at least one hair growth regulating compound selected from the group consisting of glyceryl dilaurate, apigenin, tetrahydrocurcumin, oleanolic acid, azelaic acid, sulforaphane, canavanine, pyridoxal 5-phosphate, phytic acid, tannic acid, grape seed extract, NG-nitro-L-arginine-methyl ester, benzamidine, sodium butyrate, betulinic acid, polyornithine, polyarginine, fisetin, jasmonates, methyl-jasmonate, cis-jasmone, caffeic acid phenethyl ester, delphinidin, ethyl abietate, esculetin, sorbic acid methyl ester, canaline, N-formyl-methionine, N-formyl-alanine, taurine, palmitoyl carnitine, undecanol, undecylenic acid, rutin, fusidic acid, phenyl pyruvic acid, L-isoleucine, phenyl glycine, silibinin, silymarin, L-ascorbic acid-6-palmitate, N-undecylenoyl-L-phenylalanine, and salts, derivatives and mixtures of any of the foregoing; and a dermatologically-acceptable carrier. | 2008-10-16 |
20080254056 | Green Alga Extract with High Astaxanthin Content and Method of Producing the Same - A green algal extract that contains astaxanthin at a concentration of 8 wt % or more can be obtained by cultivating an encysted green alga in a nutrient medium while supplying carbon dioxide and providing irradiation with light at a photosynthetically active photon flux input of 8000 μmol-photon/m | 2008-10-16 |
20080254057 | Combined Meningococcal Conjugates With Common Carrier Protein - Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by | 2008-10-16 |
20080254058 | Pharmaceutical Composition Comprising a Bacterial Cell Displaying a Heterologous Proteinaceous Compound - The present invention pertains to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in the manufacture of vaccines or medicaments for delivery via the mucosa. | 2008-10-16 |
20080254059 | Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby - Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g., fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 26, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for delivery and expression of heterologous genes are provided. | 2008-10-16 |
20080254060 | Genetically Engineered Equine Influenza Virus and Uses Thereof - The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 2008-10-16 |
20080254061 | Mycobacteria Expressing Hiv-1 and Malaria Antigens - Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are | 2008-10-16 |
20080254062 | USE OF AN AVIRULENT BORDETELLA MUTANT AS A LIVE VACCINE VECTOR - The present invention pertains to | 2008-10-16 |
20080254063 | Vaccines and Methods to Treat Canine influenza - The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses. | 2008-10-16 |
20080254064 | COMPOSITIONS AND METHODS FOR PRIMING MONOCYTIC DENDRITIC CELLS AND T CELLS FOR TH-1 RESPONSE - The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and/or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided. | 2008-10-16 |
20080254065 | Influenza Virus Vaccines - The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain. As the invention does not require detailed knowledge of an emerging strain, a vaccine can be provided further in advance to reduce the risk and potential effects of a human pandemic outbreak. | 2008-10-16 |
20080254066 | Nanoemulsion Vaccines - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens. | 2008-10-16 |
20080254067 | Process for the Production of an Influenza Vaccine - The present invention relates to a commercial-scale process for the production of influenza virus or antigens for prophylactic, diagnostic, immunotherapeutic or therapeutic purposes. Particularly, the invention provides a Madin-Darby Canine Kidney (MDCK)-derived, cell line and a cell culture-based process for the production of an influenza vaccine and more particularly, a human vaccine comprising influenza types A and B. | 2008-10-16 |
20080254068 | Novel Vaccine for Veterinary and Human Medicine Prophylaxis and Therapy - The present invention relates to a novel vaccine, its use for immunoprophylaxis and/or the treatment of candidamycoses in human and veterinary medicine as well as methods for its preparation, wherein said vaccine consists of the combination of the | 2008-10-16 |
20080254069 | VACCINES FOR IMMUNIZATION AGAINST HELICOBACTER - The invention relates to the immunisation of pigs against | 2008-10-16 |
20080254070 | Streptococcus pneumoniae proteins and nucleic acid molecules - Protein antigens from | 2008-10-16 |
20080254071 | Homeopathic composition for alleviating allergy symptoms - The present invention is directed towards a homeopathically designed composition comprising effective amounts of | 2008-10-16 |
20080254072 | Method For Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens - Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided. | 2008-10-16 |
20080254073 | Transdermal Patch Comprising Paroxetine - Disclosed relates to a transdermal patch comprising paroxetine that is useful to reduce the side effects accompanied with the initial high drug concentration after oral administration of paroxetine and decrease the broad metabolism of the drug in the liver. Moreover, the transdermal patch comprising paroxetine of the present invention has an excellent skin permeation rate and shows high bioavailability compared with oral administration of the drug. | 2008-10-16 |
20080254074 | COMPOSITION AND METHOD FOR REGULATING SEBUM FLOW - A skin care composition for regulating sebum flow from sebocytes is described. The composition comprises spheroids, and optionally, thickening agents and when a spheroid and sebum mixture is made upon application, the resulting mixture leaves a pleasant, silky and powdery sensation. | 2008-10-16 |
20080254075 | Cosmetic Preparation for Coloring of Eyelids and Eyebrows - An aqueous cosmetic preparation for coloring of eyelids and eyebrows contains 3-35 wt. % of an aqueous plastic dispersion based on an acrylate polymer and having a 30-50% solids content, 1-20 wt. % of at least one alcohol being ethanol and/or propanol, 2-25 wt. % of at least one moisture-retention agent, 0.2-5 wt. % of a polyoxyethylene glycerin fatty acid ester and/or a polyether-modified polysiloxane, and a colorant. The preparation has a Brookfield viscosity at 25° C. of less than 50 mPa-sec. | 2008-10-16 |
20080254076 | Composition based on silicone oil structured in rigid form, especially for cosmetic use - A physiologically acceptable composition, especially a cosmetic composition, comprising a liquid fatty phase comprising at least one silicone oil, structured with a polymer with a weight-average molecular mass ranging from 500 to 500 000, comprising at least one moiety comprising:
| 2008-10-16 |
20080254077 | Core/shell particles based on silicone compounds - The present invention relates to particles of core/shell type suitable for the encapsulation of cosmetic and/or therapeutic lipophilic active agents. It also relates to a process for preparing said particles as well as cosmetic or therapeutic compositions comprising them. | 2008-10-16 |
20080254078 | Chitosan-Based Particles - The present invention provides a new binary system of hydrophilic nanoparticles and microparticles, using chitosan and polyanionic polysaccharides carrying carboxymethyl groups, sulfate groups or carboxy plus sulfate groups. | 2008-10-16 |
20080254079 | NOVEL COMPOSITIONS CONTAINING LYSOZYME AND C-1/C-4 POLYSACCHARIDES AND USE THEREOF IN ORAL CARE, COSMETOLOGY AND DERMATOLOGY, CONTRACEPTION, UROLOGY AND GYNECOLOGY - A composition comprising a content of a lysozyme and a content of a C-1/C-4 polysaccharide is useful in oral care, cosmetology and dermatology, contraception, urology and gynecology. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR § 1.72(b). | 2008-10-16 |
20080254080 | Novel Uses of Calcium Hydroxide - A heating ventilation and air conditioning (“HVAC”) system having bacterial spore, viral, and fungal killing activity. The HVAC system components are at least partially coated with a biocidal composition having hydrated lime, soluble binder polymer mixture and humecatant are mixed in either an organic based- or water based-solvent system that is useful for coating HVAC system components. | 2008-10-16 |
20080254081 | Moist Wipe and Method of Making Same - A moist wipe having a web of fibers stabilized as with a suitable binder, and the stabilized, dry web having an anionic surface charge not greater than about 1.2 meq/Kg. A cationic functional agent in an aqueous imbuement is added to the web which is partially adsorbed by the web and a portion of the agent remaining free. Because the anionic surface charge on the substrate is relatively low, there remains in the free aqueous medium a sufficient quantity of the functional agent deliverable to the surface to achieve the desired efficacy. The resulting web will adsorb a limited amount of the cationic functional agent in the aqueous imbuement, and thereby an adequate amount of the agent remains in the solution free of the web for deliverance to the surface, thereby obviating high loadings of the imbuement and the active functional agent. | 2008-10-16 |
20080254082 | Methods for Crop Protection - The invention relates to a method for crop protection comprising administering to one or both of the crop and its environment a composition comprising a carrier; and microcapsules having a core material comprising a pesticide encapsulated by a silica shell, wherein the silica shell constitutes up to 10% w/w out of the total weight of the microcapsules, and wherein said administration gives rise to pesticide activity with immediate onset and prolonged effect. The invention further relates to a method for acute treatment of a pest-infested crop. | 2008-10-16 |
20080254083 | Dual action organic formulation to control two stages of insect pests - The present invention discloses systems and methods for controlling arthropod populations. The systems include a polymeric substrate, a semiochemical that is reactive upon an adult-stage arthropod, and an insecticide that is toxic to an immature-stage arthropod. The semiochemical may be a sex pheromone that disrupts mating behavior of the adult-stage arthropod. The insecticide may be a per os insecticide that only affects the immature-stage arthropod. The arthropod to be controlled may be gypsy moths, in which case the semiochemical may be disparlure and the insecticide may be spinosad. Further disclosed are methods for preparing systems for use in controlling arthropod populations. | 2008-10-16 |
20080254084 | Antimicrobial Preparations Having a Content of Octenidine Dihydrochloride Encapsulated in Liposomes - The invention relates to antimicrobial preparations which comprise octenidine dihydrochloride in liposomes. The invention additionally relates to a process for manufacturing the preparations and to the use of phospholipids for manufacturing antimicrobial preparations which comprise octenidine dihydrochloride. The preparations show a low cytoxicity. | 2008-10-16 |
20080254085 | Degradable Polymers Incorporating Gamma-Butyrolactone - Disclosed herein are implantable medical devices having controlled release biodegradable polymer coatings thereon wherein the polymer is formed from ring opening of γ-butyrolactone and at least one additional monomer selected from the group consisting of trimethylene carbonate, lactide, polyethylene glycol, glycolide, the monomers formed from ring opening of ε-caprolactone, 4-tert-butyl caprolactone, and N-acetyl caprolactone, and combinations thereof, and at least one drug releasable from the biodegradable polymer. Also disclosed are implantable medical devices form of the biodegradable polymers and processes for forming the polymers. | 2008-10-16 |
20080254086 | Controlled Release Compositions - Controlled release compositions for controlling release of a GnRH molecule or a GnRH analog are provided. The compositions include a GnRH molecule or GnRH analog as an active agent, and a controlled release component for controlling release of the GnRH molecule or GnRH analog from the composition. The compositions provide a sustained mean steady state plasma concentration (C | 2008-10-16 |
20080254087 | Methods For Administering Hypoglycemic Agents - The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists. | 2008-10-16 |
20080254088 | SHAPED BODIES BASED ON A CROSS-LINKED, GELATINOUS MATERIAL, METHOD FOR PRODUCING SUCH BODIES AND USE OF THE BODIES - Shaped bodies based on gelatin which have both high mechanical strength and also sufficient flexibility are provided, the shaped body comprising a cross-linked, gelatinous material which comprises gelatin and a plasticizer, the shaped body being stretched so that the gelatin molecules are oriented at least in part in a preferred direction. | 2008-10-16 |
20080254089 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES - A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment. | 2008-10-16 |
20080254090 | Porcine Islets Cultured With Porcine Sertoli Cells For Xenotransplantation - Aggregates and their method of preparation suitable for implantation into a recipient in order to produce insulin in vivo. The methods involve culturing islet cells isolated from the pancreas of donor piglets with isolated Sertoli cells from the testes of donor piglets. A preferred period of culturing is 5 days and may be followed by a purification procedure. | 2008-10-16 |
20080254091 | Multi-Layered Antiadhesion Barrier - The present invention relates to a multi-layered anti-adhesion barrier, particularly to a multi-layered anti-adhesion barrier comprising a nanofibrous structured base layer electrospun from a hydrophobic, biodegradable, biocompatible polymer and a polymer layer formed by coating a hydrophilic, biooriginated polymer on the base layer, and a method for the preparing the same. The multi-layered anti-adhesion barrier of the present invention can solve the problems of the conventional gel, solution, sponge, film or nonwoven type anti-adhesion systems, including adhesion to tissues or organs, flexibility, physical strength, ease of handling (ease of folding and bending), etc., offers improved user convenience. With a nanofibrous structure, the multi-layered anti-adhesion barrier of the present invention effectively blocks the infiltration or migration of blood and cells and promotes the healing of wounds. It is not torn or broken when folded or rolled and can be easily handled using small surgical instruments. Thus, it can minimize a foreign body reaction when used in various surgical operations. | 2008-10-16 |
20080254092 | Acellularized Biomaterial from Embryonic Stem Cells - Compositions containing acellularized biomaterial derived from differentiating pluripotent cells, for example, embryonic stem cells are provided. The acellularized biomaterial can be used to promote wound healing, promote tissue regeneration, or inhibit scarring. Methods for using the acellularized biomaterial for treating degenerative diseases are also provided. | 2008-10-16 |
20080254093 | COMPOSITIONS AND MINIMALLY INVASIVE METHODS FOR TREATING DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is described. | 2008-10-16 |
20080254094 | Biomaterials Carrying Cyclodextrines Having Improved Absorption Properties and Used for the Progressive and Delayed Release of Therapeutic Molecules - The present invention relates to a method of preparation of a biomaterial containing at least one bioactive molecule from a base biomaterial, characterized by the following successive operations carried out on the aforesaid base biomaterial:
| 2008-10-16 |
20080254095 | DELIVERY DEVICE AND METHOD FOR FORMING THE SAME - A delivery device includes a hollow container, and a plurality of biodegradable and/or erodible polymeric layers established in the container. A layer including a predetermined substance is established between each of the plurality of polymeric layers, whereby degradation of the polymeric layer and release of the predetermined substance occur intermittently. Methods for forming the device are also disclosed herein. | 2008-10-16 |
20080254096 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS CONTAINING TYROSINE KINASE INHIBITORS AND RELATED METHODS - Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions. | 2008-10-16 |
20080254098 | Neural tube birth defect reduction with folic acid delivery in catamenial hygiene products - A method and apparatus of fortifying a population of fertile age women with folic acid to reduce the incidence of neural tube birth defects involves placing folic acid either in powder, microcapsule, gel, cream, tablet, capsule or other form in or on a feminine hygiene product such as a tampon or a menstrual pad and making such products available to the population of women so that their normal use of the tampons or other feminine hygiene products will result in absorption of a sufficient amount of folic acid to satisfy RDA requirements for women who may or have become pregnant. In certain embodiments, vitamin B12 and/or other nutrients or ingredients are added to the folic acid vehicle. | 2008-10-16 |
20080254099 | Pharmaceutical Compositions Comprising Polymeric Binders with Non-Hydrolysable Covalent Bonds and Their Use in Treating Celiac Disease - A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa. | 2008-10-16 |
20080254100 | METHODS OF USING GAMMA CYCLODEXTRIN TO CONTROL BLOOD GLUCOSE AND INSULIN SECRETION - Disclosed are methods of producing a blunted postprandial glycemic response in an individual, and/or reducing postprandial insulin secretion, said methods comprising administering to the individual a nutritional or other product comprising gamma-cyclodextrin. Also disclosed are similar other methods directed toward the use of such products to provide weight and appetite control, to normalize blood glucose levels in individuals with impaired glucose tolerance, to minimize nighttime hypoglycemia in diabetic and non-diabetic patients, to prevent reactive hypoglycemia in susceptible non-diabetics, to normalize blood glucose levels in individuals with gestational diabetes or impaired glucose tolerance during gestation, and/or to provide a prolonged glycemic response during exercise. The methods are based upon the discovery that gamma-cyclodextrins are rapidly metabolized and absorbed in the small intestine, but subsequently result in a surprisingly blunted postprandial glycemic response and reduced insulin secretion. | 2008-10-16 |
20080254101 | PILOCARPINE COMPOSITIONS AND METHODS OF USE THEREOF - The present invention provides novel compositions for the delivery of pilocarpine or a pharmaceutically acceptable salt thereof across the oral mucosa, preferably across the buccal mucosa. In particular, the buffer systems in the compositions of the present invention contain an amount of a strong base that is less than the amount of a weak base, thereby increasing the stability of compositions such as chewing gum compositions and raising the pH of saliva to a pH greater than about 7.5 to facilitate the substantially complete conversion of pilocarpine from its ionized to its un-ionized form. Methods for using the compositions of the present invention for treating conditions such as dry mouth are also provided. | 2008-10-16 |
20080254102 | Orally administered agent and an orally administered agent/supporting substrate complex - With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent | 2008-10-16 |
20080254103 | Wound Dressings Comprising a Protein Polymer and a Polyfunctional Spacer - There is described a method of forming a wound dressing. The method comprises forming a protein polymer by reacting a protein with a polyfunctional spacer, or an activated derivative thereof. The polyfunctional spacer is preferably a polycarboxylic acid, especially a dicarboxylic acid, and protein polymers prepared using such spacers are suitable for a wide range of therapeutic applications, including use as wound dressings, for the delivery of therapeutically active agents to the body and as bioadhesives and sealants. | 2008-10-16 |
20080254104 | Advanced functional biocompatible polymeric matrix containing nano-compartments - The present invention provides a novel biomaterial which is a hybrid, self-assembling biopolymeric networked film that is functionalized through hydrophobic interactions with vesicles loaded with bioactive agents. The biomaterial compound is a polymeric network of hydrophobically modified chitosan scaffolds that is taken from solution and formed as a solid film. This solid state film is capable of hydrophobic interactions with the functionalized vesicles. The vesicles include one or more lamellar structures forming one or more nano-compartments that are capable of containing similar or alternative active moieties within. Use of the film results in a degradation of the chitosan scaffold thereby releasing the active moieties within the vesicles from the scaffold. Application of the current invention occurs through various delivery mechanisms and routes of administration as will be described herein. | 2008-10-16 |
20080254105 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES - The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components. | 2008-10-16 |
20080254106 | Use Of Pirlindole For The Treatment Of Diseases Which Are Characterized By Proliferation Of T-Lymphocytes And/Or Hyperproliferation Of Keratinocytes In Particular Atopic Dermatitis And Psoriasis - The present invention relates to the use of Pirlindole, if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Pirlindole and use thereof. | 2008-10-16 |
20080254107 | METHOD AND DEVICE FOR TREATING BURSITIS - The present invention relates to a method for treating a subject for a condition or inflammation associated with oedema, excess body fluids or oedema and excess body fluids, or for treating a subject for an abscess, boil, blister or cyst. The method comprises applying to the skin surface covering a body part or region affected by said condition, inflammation, abscess, boil, blister or cyst a composition capable of transdermally attracting fluids from the body part or region or its proximity, wherein said composition comprises at least one adsorptive or absorptive agent, and leaving said composition in contact with the skin for sufficient time to allow said composition to transdermally absorb or adsorb at least a portion of the body fluids from said body part or region. The present invention also relates to compositions for absorbing or adsorbing fluids from a body part or region, and which are capable of transdermally attracting fluids from body parts or regions or their proximity. | 2008-10-16 |
20080254108 | Formulations and Methods for Modulating Satiety - This disclosure relates to formulations and methods of suppressing appetite and eliciting satiety (sense of being filled) in mammals through the oral administration of an effective amount of an appetite suppressing moiety. | 2008-10-16 |
20080254109 | LOCALIZED MYOCARDIAL INJECTION METHOD FOR TREATING ISCHEMIC MYOCARDIUM - This invention relates to a method of treating ischemic or diseased myocardium by injecting a therapeutic agent, such as a gene, protein, cell or drug, into normal myocardium, preferably adjacent to an ischemic zone in the heart of a subject. The method is useful for inducing angiogenesis and collateral blood vessel formation to improve cardiac function in subjects with ischemic heart disease. The method can also be used to promote tissue regeneration in such subjects. | 2008-10-16 |
20080254110 | Composition For Enhancing Immunity and Reducing Inflammation Related to Infections - A composition and method for enhancing immunity and reducing or inhibiting inflammation related innate immune system activation while affording the body of a user protection against known detrimental byproducts of immune-response is provided. The composition comprises at least a therapeutically effective amount of vitamin C and extract of | 2008-10-16 |
20080254111 | Bandseal for peg-filled hard capsule - The present invention provides a band seal for hard capsules filled with PEG, particularly a low-molecular-weight PEG, PEG | 2008-10-16 |
20080254112 | Pharmaceutical Active-Ingredient-Containing Formulation with Coating - The invention relates to a pharmaceutical active-ingredient-containing formulation for oral administration which is coated with a single coating of a film-forming polymer, the coating comprising a mixture of at least two separating agents and no stabilizer. | 2008-10-16 |
20080254113 | Microemulsion Formulations Comprising Particular Substance P Antagonists - The present invention relates to dispersible pharmaceutical compositions in which the active agent is a substance P antagonist, in particular a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide, that is useful for the treatment and prevention of respiratory diseases including asthma and chronic obstructive pulmonary disease, bowel disorders including irritable bowel syndrome (IBS), urinary incontinence, and cough. | 2008-10-16 |
20080254114 | Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles - The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as “active ingredient,” having improved solubility in water. The nanoparticles of the composition have an effective average particle size of less than about 2,000 nm, and are useful in the treatment of asthma. The invention also relates to a multiparticulate modified release composition comprising the active ingredient that in operation delivers the drug in a pulsed or bimodal manner for the treatment of asthma. The controlled release composition comprises an immediate release component and a modified release component. The immediate release component comprises a first population of heterocyclic amide derivative, and preferably zafirlukast particles, and the modified release component comprises a second population of heterocyclic amide derivative, and preferably zafirlukast nanoparticles, and a controlled release component, wherein the combination of the immediate release and modified release components in operation delivers the active ingredient in a pulsed or bimodal manner. The heterocyclic amide derivative can be released from the multiparticulate particles in an erosable, diffusion or osmotic controlled release system. | 2008-10-16 |
20080254115 | Micropellet Containing Pellets and Method of Preparing Such Pellets - The invention provides novel pellets adapted for biologically active preparations and a novel process for preparing said pellets. The novel pellets are adapted for use in the delivery of a biologically active agent. The pellets have an inner zone comprising a plurality of micropellets which are bound together to form a pellet when the micropellets are dispersed in a matrix of an inert pharmaceutical excipient, a biologically active agent and optionally having an outer zone comprising a surface layer comprising a pharmaceutical excipient with or without a biologically active agent. The pellets will have an arcuate surface due to the manner in which they are formed. | 2008-10-16 |
20080254116 | Delta and Epsilon Crystal Forms of Imatinib Mesylate - The invention relates to the delta and epsilon crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans. | 2008-10-16 |
20080254117 | PROCESS FOR PREPARING PRAMIPEXOLE DIHYDROCHLORIDE TABLETS - The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit enhanced storage stability properties. | 2008-10-16 |
20080254118 | PROCESS FOR PREPARING PRAMIPEXOLE DIHYDROCHLORIDE TABLETS - The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit enhanced storage stability properties. | 2008-10-16 |
20080254119 | Imbedded liquid lubricants for tableting - The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided. | 2008-10-16 |
20080254120 | ORALLY-DISINTEGRATING TABLET AND MANUFACTURING METHOD THEREOF - An orally-disintegrating tablet comprises a principal agent, a sugar alcohol powder and a sugar alcohol granule, wherein the orally-disintegrating tablet has a hardness of 30 N or greater. According to the present invention, a smooth swallowing orally-disintegrating tablet, for which both the mechanical strength and the disintegration properties in the buccal cavity are favorable with using a normal tableting machine and without using special devices and the feeling on the tongue and taste are favorable, is provided. | 2008-10-16 |
20080254121 | Multi-layer melatonin composition - A multi-layered solid dosage form for oral administration for a multi-phasic controlled release of Melatonin is described. The solid dosage form is useful as a composition to promote and maintain a state of sleep in an individual. | 2008-10-16 |
20080254122 | Polymer release system - A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals. | 2008-10-16 |
20080254123 | Morphine polymer release system - A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating. | 2008-10-16 |
20080254124 | Controlled release composition - A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising a matrix comprising the active substance, the matrix being erodible in the aqueous medium in which the composition is to be used, and a coating having at least one opening exposing at least one surface of said matrix, the coating comprising a first cellulose derivative which has thermoplastic properties and which is substantially insoluble in the aqueous medium in which the composition is to be used, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and a filler. The coating is a coating which crumbles and/or erodes upon exposure to the aqueous medium such as a body fluid. The first cellulose derivative may be, e.g., ethylcellulose, cellulose acetate, cellulose propionate or cellulose nitrate, and the second cellulose derivative may be, e.g. methylcellulose, carboxymethylcellulose or salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose or hydroxymethylpropylcellulose. | 2008-10-16 |
20080254125 | Processing of Chitosan and Chitosan Derivatives - An article containing N-acylchitosan is manufactured by a process comprising the steps of providing a mixture containing chitosan and/or N-acylchitosan, and extruding the mixture to form an N-acylchitosan hydrogel. Alternatively, the process comprising the steps of providing a chitosan and/or N-acylchitosan hydrogel, and extruding the hydrogel. An article with a memorized shape is formed by fixing the N-acylchitosan hydrogel in a desired shape, and at least partially drying the fixed hydrogel. A patient is treated by injecting the N-acylchitosan hydrogel. | 2008-10-16 |
20080254126 | Composition comprising nanoparticle ginkgo biloba extract with the effect of brain function activation - To supply the | 2008-10-16 |
20080254127 | Inhalation particles incorporating a combination of two or more active ingredients - Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders. | 2008-10-16 |
20080254128 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 2008-10-16 |
20080254129 | Use of avian anti-methanogen antibodies for reduction of methane production - Herein, it is shown that strong specific anti-methanogen avian antibodies can be produced when chickens are immunized with an optimal dose of methane producing bacterial antigen (methanogen) formulated with an appropriate adjuvant. The antibodies can in turn be used to reduce methane gas production from an animal by administering an effective amount of the anti-methanogen antibodies to the animal, thereby reducing methane gas evolved by the animal compared to an untreated or mock treated control animal of similar age and condition. | 2008-10-16 |
20080254130 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction - The present invention relates to a topical method of treatment for dysfunction of certain dermal enzymes, and the treatment of skin condition or disorder caused by said dysfunction. The said method of treatment consists of (i) an extra-cellular, matrix metalloprotease regulating agent, and (ii) an intra-cellular ubiquitin—proteasome regulating agent, and (iii) an epidermal melanocyte-regulating agent; and, wherein, said extra-cellular agent, said intracellular agent, and said epidermal agent can, surprisingly and unexpectedly, be a single multi-function compound having chemical formula (I). Additionally, the method of the present invention provides treatment of skin condition or disorder caused by dysfunction of said dermal enzymes; wherein said skin disorder is skin aging, skin wrinkles, dark skin, age spots, acne, skin inflammation, loss of cellular antioxidants, loss of collagen, loss of skin pliability, loss of skin suppleness, oily skin, or a combination thereof: | 2008-10-16 |
20080254131 | CONTROLLED-RELEASE GALANTAMINE FORMULATIONS - Controlled-release galantamine formulations, including controlled-release particles, pellets, granules, and spheres are described. Controlled-release particles, pellets, granules, and spheres with immediate release top-coat are also described. Method of preparing such formulations and method of treating a variety of disorders are also disclosed. | 2008-10-16 |
20080254132 | High pressure spray-dry of bioactive materials - This invention provides compositions and methods providing, e.g., stable powder particles containing bioactive materials. The methods include, e.g., high pressure spraying of the bioactive materials in solution or suspension, with viscosity enhancing agents and/or surfactants. Compositions of the invention provide, e.g., high initial purity, high stability in storage, and reconstitution at high concentrations. | 2008-10-16 |
20080254133 | Microgel Particle - The present invention relates to compositions comprising a pH-responsive microgel particle, wherein the particle is adapted to undergo a conformational change in response to a variation in pH. The compositions may be used as medicaments for treating a disease characterised by damaged or degenerated soft tissues (e.g. intervertebral discs). | 2008-10-16 |
20080254134 | METHOD FOR INDUCING A CELL-MEDIATED IMMUNE RESPONSE AND IMPROVED PARENTERAL VACCINE FORMULATIONS THEREOF - A method of inducing either a T | 2008-10-16 |
20080254135 | RESVERATROL-CONTAINING COMPOSITIONS FOR GENERAL HEALTH AND VITALITY - The present invention is directed towards an orally administered composition comprising multiple plant extracts, which are characterized as having high ORAC values, and promote an increase in a mammal's dietary intake of antioxidant and polyphenols to a therapeutically effective amount. The ingredients of the present compositions represent a broad spectrum of polyphenols providing antioxidant activity for the purpose of improving general health and vitality by enhancing cardioprotection and immune system functions. The composition of the present invention comprises an extract of | 2008-10-16 |
20080254136 | Antiprotozoal Agent - The present invention provides an antiprotozoal agent, which is particularly preferred as an antileishmanial agent. Specifically, the present invention is directed to an antiprotozoal agent comprising, as an active ingredient, a compound of Formula (I): | 2008-10-16 |
20080254137 | Treatment of autoimmune disorders using detoxified cobratoxin - Autoimmune disorders are widespread diseases with many manifestations. Immune regulatory dysfunction is central to the progress of these diseases. The control this dysfunction can be achieved through intervention in the immune pathways. The balance of regulatory cytokines is central to a correctly functioning immune system and is a target for therapeutic intervention. Herein is described the induction of the regulatory cytokines, interferon gamma and interleuking 27, as a method to treat autoimmune diseases and a method by which such regulatory cytokines can be induced using a detoxified cobra neurotoxin composition. | 2008-10-16 |
20080254138 | EXTRACELLULAR MATRIX TO RECRUIT STEM CELLS TO A SITE OF MALIGNANCY - The invention is to a method of recruiting stem cells to a site of malignancy by contacting the site with exogenous mammalian extracellular matrix in the form of a sheet article, or a composition comprising particulate extracellular matrix, or emulsion or gel extracellular matrix. | 2008-10-16 |
20080254139 | METHODS AND COMPOSITIONS TO TREAT OVARIAN CANCER - The invention is a method of treating ovarian cancer by contacting a post-surgical site of an ovarian cancer patient with a composition or a sheet article comprising extracellular matrix to inhibit cancer cell attachment, promote wound healing after the surgery, reduce scar formation at the surgical site, regenerate lost tissue, and prevent tumor recurrence at the site or in the peritoneum generally. | 2008-10-16 |
20080254140 | Combination Methods and Therapies for Treating Opthalmic Conditions with 13-Cis-Retinyl Derivatives - Described herein are combination methods, compositions and therapies for treating ophthalmic conditions or diseases arising from, associated with or leading to the overproduction of waste products in the visual cycle. Agents included within these combinations are 13-cis-retinyl derivatives; other agents included within these combinations are selected from vitamins, antioxidants, minerals, inducers of nitric oxide production, anti-inflammatory agents, and negatively-charged phospholipids. Such combination methods may be used as single or multiple administration therapies, or in combination with other agents or therapies. | 2008-10-16 |
20080254141 | ANTI-BACTERIAL, ANTI-VIRUS, AND ANTI-FUNGUS COMPOSITION, ITS PREPARATION AND USE - The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard. Additionally, the present composition can be applied to human being such as applying to hand, foot, genital organs, oral cavity, and the like in a lower dose to attain the effect of destroying of bacteria, viruses, and fungi. | 2008-10-16 |
20080254142 | COMPOSITIONS AND METHODS FOR NUTRITION SUPPLEMENTATION - The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects. | 2008-10-16 |
20080254143 | COMPOSITION FOR IMPROVING IMMUNE SYSTEM HEALTH - A composition and method for enhancing the immune system of an individual is provided. The present invention enhances the functioning of the immune system through increasing the production of certain cytokines, inhibiting viral adhesion and interfering in the viral replication process. The severity and duration of infections resulting from the common cold and associated viral infections are also reduced through the oral administration of the composition of the present invention. The composition of the present invention comprises at least an effective amount of an extract of wolfberry ( | 2008-10-16 |